{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:53:10Z","timestamp":1785509590549,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A significant improvement in clinical signs was demonstrated with abrocitinib relative to placebo in adolescents with moderate\u2010to\u2010severe atopic dermatitis (AD) in three phase 3, randomized, double\u2010blinded, placebo\u2010controlled studies (JADE TEEN [ClinicalTrials.gov, NCT03796676], JADE MONO\u20101 [NCT03349060] and JADE MONO\u20102 [NCT03575871]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the impact of abrocitinib on patient\u2010reported signs\/symptoms, including sleep loss and quality of life among adolescents with moderate\u2010to\u2010severe AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>JADE TEEN, JADE MONO\u20101 and JADE MONO\u20102 were conducted in the Asia\u2010Pacific region, Europe and North America and included patients aged 12\u201317\u2009years with moderate\u2010to\u2010severe AD and inadequate response to \u2265 4 consecutive weeks of topical medication or treatment with systemic therapy for AD. Patients were randomly assigned (1\u2009:\u20091\u2009:\u20091, JADE TEEN; 2\u2009:\u20092\u2009:\u20091, JADE MONO\u20101\/\u20102) to receive once\u2010daily oral abrocitinib (200 or 100\u2009mg) or placebo for 12\u2009weeks in combination with topical therapy (JADE TEEN) or as monotherapy (JADE MONO\u20101\/\u20102). Data from adolescent patients in JADE MONO\u20101\/\u20102 were pooled for these analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 12, more adolescents treated with abrocitinib (200 or 100\u2009mg) vs. placebo achieved a\u2009\u2265\u20094\u2010point improvement from baseline in the Patient\u2010Oriented Eczema Measure in JADE TEEN (83.9% and 77.0% vs. 60.2%) and JADE MONO\u20101\/\u20102 (83.0% and 69.4% vs. 43.5%) and a\u2009\u2265\u20096\u2010point improvement from baseline in the Children\u2019s Dermatology Life Quality Index in JADE TEEN (73.8% and 67.5% vs. 56.5%) and JADE MONO\u20101\/\u20102 (70.0% and 57.1% vs. 19.0%). Significant improvements in SCORing Atopic Dermatitis Visual Analog Scale for sleep loss scores were demonstrated with abrocitinib vs. placebo at weeks 2\u201012 in JADE TEEN and JADE MONO\u20101\/\u20102.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patient\u2010reported signs\/symptoms, including reduction of sleep loss and quality of life, were substantially improved with abrocitinib monotherapy or combination therapy relative to placebo in adolescents with moderate\u2010to\u2010severe AD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17792","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T12:10:58Z","timestamp":1636287058000},"page":"422-433","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate\u2010to\u2010severe atopic dermatitis: an analysis of patient\u2010reported outcomes"],"prefix":"10.1111","volume":"36","author":[{"given":"M.J.","family":"Cork","sequence":"first","affiliation":[{"name":"Sheffield Dermatology Research University of Sheffield Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McMichael","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-6807","authenticated-orcid":false,"given":"J.","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Dermatology Stanford University Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Valdez","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rojo","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Myers","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.040"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000034"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19580"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00459-8"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.23736\/S2784-8671.20.06654-7","article-title":"Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)","volume":"156","author":"Calzavara\u2010Pinton P","year":"2021","journal-title":"Ital J Dermatol Venereol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3653"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12632"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.02.025"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.70"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16892"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1160-7"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9868-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0128-z"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.055"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16163"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12590"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16367"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00333-2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12437"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00474-9"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247298"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15179"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000486"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00265-y"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2480"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15480"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13452"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17792","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:40:41Z","timestamp":1693104041000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/jdv.17792"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17792","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,4]]},"assertion":[{"value":"2021-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}